-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Elderly inflammatory bowel disease (senile inflammatory bowel disease, IBD) generally refers to patients with inflammatory bowel disease who are older than 60 or 65 years old at the time of onset.
Elderly inflammatory bowel disease (senile inflammatory bowel disease, IBD) generally refers to patients with inflammatory bowel disease who are older than 60 or 65 years old at the time of onset.
Researchers conducted a retrospective cohort study of adults over 65 years of age who had IBD and started anti-TNF-α drugs and vedolizumab
Infect
In total, there were 1152 patients treated with anti-TNF-α and 480 patients treated with vedolizumab
It was shown that the risk of infection-related hospitalization in vedolizumab users was reduced, while the risk of infection -related infection in patients treated with anti-TNF-α was not significantly reduced
This study confirmed that elderly patients with IBD who received vedolizumab had a lower risk of infection-related hospitalization compared with patients who started anti-tumor necrosis factor therapy
Bharati Kochar.
Vedolizumab is associated with a lower risk of serious infections than anti-TNF agents in older adults.
Leave a message here